The Therapeutic Goods Administration has approved Sanofi’s Altuviiio (efanesoctocog alfa) for the treatment and prophylaxis of bleeding episodes in adults and children with haemophilia A, giving Australian clinicians access to a factor VIII replacement therapy engineered for once-weekly dosing. The approval follows Altuviiio’s earlier authorizations in the United States and other markets and extends its reach into the Asia-Pacific region.

Haemophilia A results from a deficiency in clotting factor VIII, requiring regular replacement therapy to prevent spontaneous bleeding into joints and soft tissue. Conventional factor VIII products typically require infusions two to three times per week because the protein is cleared from circulation relatively quickly. Altuviiio addresses that limitation by fusing factor VIII to a von Willebrand factor fragment and an Fc domain, extending its circulating half-life to three to four times that of standard factor VIII products and enabling sustained protection with a single weekly infusion for most patients.

Clinical trial data supporting the therapy showed low annualized bleeding rates in both previously treated adults and children, with the extended dosing interval cited by patients and caregivers as a meaningful reduction in treatment burden compared to more frequent infusion schedules. For a country the size of Australia, where a portion of the haemophilia population lives outside major metropolitan centers, reducing infusion frequency carries practical benefits beyond the clinical endpoints, easing logistics for families managing home infusion programs.

The approval lands at a moment when Australia’s position as a destination for early and mid-phase clinical research continues to strengthen, aided by the country’s research and development tax incentive, established site network and TGA’s reputation for rigorous but efficient device and drug evaluation. Specialist contract research organizations operating in the Australian and New Zealand market, including UNIQ Trials, have highlighted this combination of regulatory credibility and cost efficiency as a draw for global sponsors evaluating where to run haematology and rare disease trials, a dynamic that extends well beyond any single product approval.

Sanofi will need to work through Australia’s Pharmaceutical Benefits Scheme listing process before Altuviiio becomes broadly subsidized for patients, a step that typically follows TGA registration by months rather than being automatic. Until a PBS listing is secured, access is likely to be concentrated among patients able to obtain the therapy through hospital formularies or clinical trial continuation pathways, a familiar sequence for specialty biologics entering the Australian market.

Altuviiio adds to a haemophilia A treatment landscape in Australia that already includes standard and extended half-life factor VIII products alongside Roche’s emicizumab, a non-factor replacement antibody administered less frequently but through a different mechanism of action. Clinicians will now have a broader set of tools to match dosing frequency, bleeding phenotype and patient preference, reinforcing a broader trend toward individualized haemophilia management rather than one-size-fits-all replacement schedules.